08.22.24
On August 9, Maryland’s Prescription Drug Affordability Board (PDAB) released its draft action plan for establishing upper payment limits (UPLs) for drugs identified as causing or likely to cause affordability challenges.
On August 15, 2024, the Centers for Medicare & Medicaid Services (CMS) announced the “maximum fair prices (MFPs)” for the first 10 drugs subject to the Medicare drug negotiation program.
08.21.24
The Federal Trade Commission (FTC or Commission) has issued a final rule prohibiting fake consumer reviews and testimonials.
In light of the recent Supreme Court case of Connelly v. Internal Revenue Service, owners of closely held businesses may need to reconsider their plan to buy out a deceased owner’s stake in a business with life insurance proceeds.
Earlier this month, the Department of Justice (DOJ) launched its anticipated Criminal Division Corporate Whistleblower Awards Pilot Program (the “Pilot Program”), which went into effect on August 1, 2024, and will continue for three years.
08.20.24
CMS recently reinforced its commitment to prohibiting pooling arrangements. Given CMS’s position, provider groups with pooling arrangements will want to consider alternative approaches.
08.15.24
A class action against generate artificial intelligence (AI) companies cleared initial hurdles this week in the U.S. District Court for the Northern District of California, which permitted claims of direct and contributory copyright and trademark infringement to proceed, while dismissing other ...
08.14.24
On August 8, a coalition of 15 state attorneys general sued CMS in the North Dakota federal court seeking to overturn a May 2024 CMS final rule making Deferred Action for Childhood Arrivals (DACA) recipients eligible for premium tax credits on the Marketplace.
08.13.24
The Centers for Medicare & Medicaid Services (CMS) is required to make public by September 1 the “maximum fair prices” (MFP) that CMS is setting for the first ten drugs subject to the Medicare Drug Price Negotiation Program (Negotiation Program) under the Inflation Reduction Act of ...
In 2019, home sellers brought a series of class-action lawsuits against the National Association of Realtors (NAR) and several national real estate brokerages, alleging that the defendants conspired in anticompetitive practices to inflate broker commissions in violation of the Sherman Antitrust Act.